Mechanism-matched Helicobacter pylori treatment in the potassium-competitive acid blocker era
Abstract
Helicobacter pylori infection remains common worldwide and causes chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Eradication therapy has become less reliable as resistance to clarithromycin, metronidazole, and levofloxacin has reduced the performance of older empiric regimens. Potassium-competitive acid blockers (P-CABs), molecular resistance testing, fecal susceptibility assays, and new antimicrobial strategies have changed treatment selection, but none removes the need to match regimen design to microbial biology and antibiotic activity. This narrative review argues that H. pylori management is shifting from empiric eradication toward mechanism-matched therapy. The framework links gastric niche biology, acid acclimation, adhesion, virulence signaling, immune evasion, resistance mechanisms, acid suppression, and partner-antibiotic selection. Recent randomized trials show the strengths and limits of this approach. Vonoprazan-based regimens improve acid suppression and can outperform proton pump inhibitor-based triple therapy in clarithromycin-resistant infection, but rescue-treatment trials show that potent acid suppression alone is insufficient when the partner antibiotic is poorly matched. Molecular testing-guided therapy and fecal molecular susceptibility testing provide practical ways to align antibiotic selection with resistance mechanisms. Rifasutenizol adds a pathogen-targeted option supported by phase…
Read the paper
Related studies
- Photochemical behavior of levofloxacin
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Synthesis of [11C]levofloxacin
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.